

Form 51-102F3
Material Change Report

1. Name and Address of Company

Enttheon Biomedical Corp.
Suite 720 - 999 W Broadway Street
Vancouver, BC
V5Z 1K5
(the "Company")

2. Dates of Material Change(s)

January 3, 2025

3. News Release(s)

News release was issued on January 6, 2025 and disseminated via Stockwatch pursuant to section 7.1 of National Instrument 51-102.

4. Summaries of Material Changes

The Company is pleased to announce that, further to its news releases dated December 2, 2024 and December 24, 2024, it has closed a non-brokered private placement for total gross proceeds of CDN\$500,000 (the "Placement"). The Company has allotted and issued 5,000,000 units (the "Units") at a price of CDN\$0.10 per Unit.

5. Full Description of Material Changes

News Release dated January 6, 2025— See Schedule "A".

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

7. Omitted Information

No information has been omitted.

8. Executive Officer

Mr. Timothy Ko, President, CEO and Director of the Company, is knowledgeable about the material change contained herein and may be reached at (604) 562-3932.

9. Date of Report

This report is dated January 6, 2025

SCHEDULE "A"
to the Material Change Report dated January 6, 2025

Entheon Biomedical Announces Closing of Private Placement Financing

VANCOUVER, BC, January 6, 2025 – Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("**Entheon**" or the "**Company**") is pleased to announce that, further to its news releases dated December 2, 2024 and December 24, 2024, it has closed a non-brokered private placement for total gross proceeds of CDN\$500,000 (the "**Placement**").

The Company has allotted and issued 5,000,000 units (the "**Units**") at a price of CDN\$0.10 per Unit. Each unit consists of one common share of the Company and one transferable share purchase warrant, with each warrant entitling the holder to acquire one additional common share at an exercise price of CDN\$0.15 for a period of 24 months from the date of issuance.

The Company will use the proceeds from the Placement towards general working capital purposes. All securities issued under the Placement are subject to a hold period of four months and one day expiring on May 4, 2025.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,

Timothy Ko, CEO, President and Director

For more information, please contact the Company at:

Entheon Biomedical Corp.

Timothy Ko, CEO

timothy@entheonbiomedical.com

<https://entheonbiomedical.com>

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.